Skip to main content
OpenTrials

Clinical trial condition

Acute Myeloid Leukemia With KMT2A Rearrangement

Explore clinical trials studying Acute Myeloid Leukemia With KMT2A Rearrangement. Study availability and eligibility vary by location and protocol.

2 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Acute Myeloid Leukemia With KMT2A Rearrangement trial results

Recruiting

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

NCT05886049

Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, +8 more
Locations
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
View all 22 locations
View Trial Details
Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

NCT06222580

Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, +9 more
Locations
  • UNC Hospitals, University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • University of Pennsylvania Philadelphia, Pennsylvania, United States
  • University of Wisconsin Carbone Cancer Center Madison, Wisconsin, United States
View Trial Details

Related conditions